Normalized Income after Taxes (Quarterly)

Normalized Income after Taxes: A company's after tax profit or loss smoothed out by elimination of all non-recurring items.

Cytokinetics, Incorporated (CYTK) had Normalized Income after Taxes of $-206.03M for the most recently reported fiscal quarter, ending 2026-03-31.

Quarterly Annual

Figures for fiscal quarter ending 2026-03-31

Income Statement Financials
Revenue	$19.36M
Net Income	$-206.03M
Cost of Goods Sold	$2.55M
Gross Profit	$16.80M
Operating Expenses	$202.97M
Operating Income	$-183.62M
Non-Operating Income/Expense	$-22.41M
Pre-Tax Income	$-206.03M
Normalized Pre-Tax Income	$-206.03M
Income after Taxes	$-206.03M
Income from Continuous Operations	$-206.03M
Consolidated Net Income/Loss	$-206.03M
Normalized Income after Taxes	$-206.03M
EBIT	$-183.62M
EBITDA	$-180.24M
Weighted-Average Shares Outstanding (Basic)	123.27M
Weighted-Average Shares Outstanding (Diluted)	123.27M
Earnings per Share (EPS) (Basic)	$-1.67
Earnings per Share (EPS) (Diluted)	$-1.67
Balance Sheet Financials
Current Assets	$839.47M
Property, Plant, and Equipment	$82.44M
Long-Term Assets	$434.01M
Total Assets	$1.27B
Current Liabilities	$199.19M
Long-Term Debt	$1.12B
Long-Term Liabilities	$1.90B
Total Liabilities	$2.10B
Common Equity	$-826.57M
Tangible Shareholders Equity	$-826.57M
Shareholders Equity	$-826.57M
Common Shares Outstanding	124.24M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$-145.46M
Cash Flow from Investing Activities	$145.49M
Cash Flow from Financial Activities	$7.77M
Beginning Cash	$125.63M
End Cash	$132.95M
Increase/Decrease in Cash	$7.32M
Stock-Based Compensation	$30.39M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	4.21
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	3.84
Debt to Equity Ratio	-1.41
Gross Margin	86.81%
Operating Margin	-948.69%
EBIT Margin	-948.69%
EBITDA Margin	--
Pre-Tax Profit Margin	-1064.48%
Profit Margin	-1064.48%
Free Cash Flow	$-151.39M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.02
Inventory Turnover	16.57
Receiveable Turnover	2.84
Days Sales in Receivables	31.75
Return on Equity	24.93%
Return on Tangible Equity	24.93%
Return on Assets	-16.18%
Return on Investments	-70.76%
Book Value Per Share	$-6.65
Free Cash Flow per Share	$-1.23
Operating Cash Flow per Share	$-1.18

Data from Zacks Investment Research, Inc.